CO6541596A2 - Tratamiento de neurotoxicidad asociada con combinaciones de 5-fu o sus profarmacos e inhibidores dpd - Google Patents
Tratamiento de neurotoxicidad asociada con combinaciones de 5-fu o sus profarmacos e inhibidores dpdInfo
- Publication number
- CO6541596A2 CO6541596A2 CO12078833A CO12078833A CO6541596A2 CO 6541596 A2 CO6541596 A2 CO 6541596A2 CO 12078833 A CO12078833 A CO 12078833A CO 12078833 A CO12078833 A CO 12078833A CO 6541596 A2 CO6541596 A2 CO 6541596A2
- Authority
- CO
- Colombia
- Prior art keywords
- dpd
- inhibitors
- professionals
- combinations
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan métodos para mejorar laadministración y dosificación de los inhibidores de DPD encombinación con 5-FU y/o profármacos de 5-FU, quecomprende primero la administración a un paciente que lonecesite un inhibidor de DPD que elimina sustancialmentela actividad de la enzima en los tejidos tanto nerviosos yno-nerviosos dentro del paciente y, posteriormente, laadministración de 5-FU o un profármaco de 5-FU, endonde el nivel de 5-FU o de 5-FU generado a partir de unprofármaco está en exceso sustancial del inhibidor de DPDen el paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25144909P | 2009-10-14 | 2009-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6541596A2 true CO6541596A2 (es) | 2012-10-16 |
Family
ID=43466528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12078833A CO6541596A2 (es) | 2009-10-14 | 2012-05-14 | Tratamiento de neurotoxicidad asociada con combinaciones de 5-fu o sus profarmacos e inhibidores dpd |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8658618B2 (es) |
| EP (1) | EP2488182B1 (es) |
| JP (2) | JP2013508293A (es) |
| KR (1) | KR20120127709A (es) |
| CN (1) | CN102811721A (es) |
| AU (1) | AU2010306698B2 (es) |
| BR (1) | BR112012008951A2 (es) |
| CA (1) | CA2777546C (es) |
| CO (1) | CO6541596A2 (es) |
| EA (1) | EA201270551A1 (es) |
| ES (1) | ES2644237T3 (es) |
| IL (1) | IL219179A0 (es) |
| MX (1) | MX2012004383A (es) |
| WO (1) | WO2011047195A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089004A1 (en) * | 2012-12-04 | 2014-06-12 | Adherex Technologies, Inc. | Methods for treating 5-fluorouracil prodrug non-responsive cancer patients |
| CN106692173A (zh) * | 2015-11-18 | 2017-05-24 | 北京诺普德医药科技有限公司 | 一种抗肿瘤复方组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5687599A (en) | 1979-12-19 | 1981-07-16 | Yamasa Shoyu Co Ltd | E 55 22halogenovinyl arabinofuranosyluracil and its preparation |
| GB8629892D0 (en) | 1986-12-15 | 1987-01-28 | Wellcome Found | Antiviral compounds |
| US5157114A (en) | 1988-08-19 | 1992-10-20 | Burroughs Wellcome Co. | 2',3'-dideoxy-3'-fluoro-5-ethyngluridine |
| ES2111569T3 (es) | 1990-07-19 | 1998-03-16 | Wellcome Found | Inactivadores de enzimas. |
| GB9020930D0 (en) * | 1990-09-26 | 1990-11-07 | Wellcome Found | Pharmaceutical combinations |
| US5476855A (en) | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| NZ330360A (en) | 1997-06-02 | 1999-03-29 | Hoffmann La Roche | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| CN101068549A (zh) | 2004-12-03 | 2007-11-07 | 阿迪赫里克斯技术公司 | 与5－fu和5－fu前药组合施用dpd抑制剂的方法 |
-
2010
- 2010-10-14 EA EA201270551A patent/EA201270551A1/ru unknown
- 2010-10-14 WO PCT/US2010/052734 patent/WO2011047195A1/en active Application Filing
- 2010-10-14 ES ES10768670.1T patent/ES2644237T3/es active Active
- 2010-10-14 BR BR112012008951A patent/BR112012008951A2/pt not_active IP Right Cessation
- 2010-10-14 MX MX2012004383A patent/MX2012004383A/es not_active Application Discontinuation
- 2010-10-14 JP JP2012534373A patent/JP2013508293A/ja active Pending
- 2010-10-14 AU AU2010306698A patent/AU2010306698B2/en active Active
- 2010-10-14 US US12/904,974 patent/US8658618B2/en active Active
- 2010-10-14 EP EP10768670.1A patent/EP2488182B1/en active Active
- 2010-10-14 CA CA2777546A patent/CA2777546C/en active Active
- 2010-10-14 KR KR1020127012289A patent/KR20120127709A/ko not_active Application Discontinuation
- 2010-10-14 CN CN2010800562916A patent/CN102811721A/zh active Pending
-
2012
- 2012-04-15 IL IL219179A patent/IL219179A0/en unknown
- 2012-05-14 CO CO12078833A patent/CO6541596A2/es not_active Application Discontinuation
-
2015
- 2015-09-29 JP JP2015190757A patent/JP2016014051A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201270551A1 (ru) | 2012-12-28 |
| ES2644237T3 (es) | 2017-11-28 |
| JP2013508293A (ja) | 2013-03-07 |
| EP2488182B1 (en) | 2017-07-19 |
| AU2010306698B2 (en) | 2016-05-26 |
| CN102811721A (zh) | 2012-12-05 |
| US8658618B2 (en) | 2014-02-25 |
| MX2012004383A (es) | 2012-08-23 |
| KR20120127709A (ko) | 2012-11-23 |
| BR112012008951A2 (pt) | 2019-09-24 |
| CA2777546C (en) | 2019-11-05 |
| IL219179A0 (en) | 2012-06-28 |
| AU2010306698A1 (en) | 2012-05-17 |
| EP2488182A1 (en) | 2012-08-22 |
| CA2777546A1 (en) | 2011-04-21 |
| US20110130359A1 (en) | 2011-06-02 |
| JP2016014051A (ja) | 2016-01-28 |
| WO2011047195A1 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201400095A (es) | Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa. | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
| NI201200030A (es) | Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas. | |
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| CL2008003901A1 (es) | Uso de un inhibidor de hedgehog para extender la sobrevida libre de recidiva en un paciente con cancer, que se encuentra en quimioterapia o ha sido tratado previamente con quimioterapia. | |
| CL2015002807A1 (es) | Terapia de combinación | |
| NI201200128A (es) | Identificación de mutación de lkb1 como un biomarcador predictivo de sensibilidad a los inhibidores de cinasa de tor. | |
| NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| NZ594365A (en) | Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
| NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
| TR201902884T4 (tr) | Mmp akti̇f vasküler bozucu ajanlar. | |
| UY32546A (es) | Composiciones y metodos para tratar cancer | |
| CO6541596A2 (es) | Tratamiento de neurotoxicidad asociada con combinaciones de 5-fu o sus profarmacos e inhibidores dpd | |
| DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek | |
| NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| GT201300148A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek | |
| CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek | |
| ECSP13012736A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |